Overall Survival With Ixazomib Combo Trended Toward Benefit in Relapsed Myeloma With Adverse Prognostics


Final overall survival results from TOURMALINE-MM1 failed to show statistical significance of an ixazomib combination for relapsed/refractory multiple myeloma overall.

Despite showing the longest overall survival (OS) results for lenalidomide/dexamethasone (Rd)–based triplets in a phase 3 trial of relapsed or refractory multiple myeloma (RRMM), ixazomib (Ninlaro) plus Rd failed to induce statistically significant benefit over placebo/Rd in the final read-out from the phase 3 TOURMALINE-MM1 study (NCT01564537) reported in the Journal of Clinical Oncology.

The investigators on the trial indicated that imbalances in subsequent therapies, such as the CD38-targeting agent daratumumab (Darzalex) and proteasome inhibitors, may have confounded the OS results in this population.

“Although the slight favorable trend in OS seen with ixazomib-Rd versus placebo-Rd at this final analysis of TOURMALINE-MM1 was not significant, these results were obtained in the context of the longest median OS reported to date in phase III studies of Rd-based therapy in RRMM,” reported investigators of the study.

The double-blind, placebo-controlled study randomized patients with relapsed or refractory disease in a 1:1 fashion to ixazomib-Rd (n = 360) or placebo-Rd (n = 362). On days 1, 8, and 15 of each 28-day cycle, patients received 4 mg of ixazomib or placebo. On days 1 through 21 in both arms, patients received lenalidomide at 25 mg; 40 mg of dexamethasone was administered on days 1, 8, 15, and 22.

OS was a secondary end point and assigned in the intent-to-treat (ITT) population as well as in those with del(17p) or high-risk and expanded high-risk cytogenetics. The primary end point was progression-free survival (PFS).

Median follow-up for OS was 85.0 and 85.1 months in the ixazomib-Rd and placebo-Rd arms. In the ITT population, 484 patients (67%) had died, of whom 240 (66.7%) and 244 (67.4%) were treated in the ixazomib-Rd and placebo-Rd arms, respectively. At the last point of contact, 113 (31.4%) and 116 (32%) were still alive.

In the ixazombi-Rd arm, median OS was 53.6 months (95% CI, 49.25-62.95) and in the placebo-Rd arm versus 51.6 months (95% CI, 44.78-59.14) in the placebo group (HR, 0.939; 95% CI, 0.784-1.125; P = .495).

Patients with del(17p) on ixazomib-Rd showed an OS benefit (HR 0.916; 95% CI, 0.516-1.626), as did those with high-risk cytogenetics (HR 0.870; 95% CI, 0.580-1.305), or expanded-risk cytogenetics (HR 0.862; 95% CI, 0.660-1.124).

For patients who did receive subsequent therapy in the ixazomib-Rd arm, the median OS was 54.3 months (95% CI, 49.84-62.95) versus the placebo-Rd arm at 58.1 months (95% CI 50.30-60.94; HR 0.985; 95% CI, 0.800-1.213). In patients who did not receive subsequent therapy, OS was 50.4 months (95% CI, .800 to 1.213) compared with 31.5 months (95% CI, 22.70 to 50.17), respectively (HR 0.877; 95% CI, 0.603 to 1.275).

Grade 3 or higher adverse effects occurring in less than 5% of patients included thrombocytopenia (21.3% with ixazomib-Rd vs 10.3% with placebo) and diarrhea (10% vs 3.1%, respectively).

“Although the slight trend in favor of ixazomib-Rd in the ITT population was not statistically significant, greater magnitudes of OS benefit (lower HRs) were observed in predefined patient subgroups with adverse-risk characteristics, including more heavily pretreated patients, patient’s refractory to prior treatment, patients with stage III [myeloma], and those with high-risk or expanded high-risk cytogenetics,” the investigators of the study wrote.

Given its convenience as an all-oral treatment regimen that confers PFS benefit in this group of patients, the investigators concluded that ixazomib-Rd will continue to represent an important therapy option for these patients.


Richardson PG, Kumar SK, Masszi T, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [published online ahead of print, 2021 Jun 11]. J Clin Oncol. 2021;JCO2100972. doi:10.1200/JCO.21.00972

Related Videos
Experts on MM
Experts on MM
Experts on multiple myeloma
Experts on multiple myeloma
Experts on multiple myeloma
Experts on MM
Experts on MM
Experts on multiple myeloma
Related Content